RICOVER-60 patients with VDD ( 8 ng/mL ) and vitamin D levels more than 8 ng/mL treated with rituximab had 3-year event-free survival ( EFS ) of 59 % and 79 % and 3-year overall survival ( OS ) of 70 % and 82 % , respectively .